Dược phẩm 2 新闻 →

DBD

Dược - Trang thiết bị y tế Bình Định

50,200
+0.20%
市值 945.3B
数据截至 2026-06-05 · 来源：越南公开市场数据

DBD is a Vietnam-listed stock for Dược - Trang thiết bị y tế Bình Định in the Dược phẩm sector. The latest tracked close is 50,200 VND, +0.20% on the session. Aveluro has analyzed 3 Vietnamese financial news articles mentioning DBD, with positive as the dominant sentiment; the latest catalyst is strategic partnership: Bidiphar (DBD) 携手Citek启动大规模数字化转型，升级SAP S/4HANA云系统.

当前重点

最新价格
50,200 VND · +0.20%
主要情绪
Positive · 3 已分析文章
最新催化剂
strategic partnership
流动性
低
数据截至
2026-06-05

Bidiphar (DBD) 携手Citek启动大规模数字化转型，升级SAP S/4HANA云系统

提示: 不构成投资建议。 · Aveluro 如何计算: Aveluro 结合提取的事件事实、来源可信度、股票背景和市场数据。评分是确定性研究信号，并非投资建议。

5.8
持有
情绪
+0.00
影响力
0.50
动量
-0.31
基本面
+0.00
成交量
0.00

Want to trade DBD? Compare brokers for Vietnam stocks.

Foreign investors need a broker that can handle Vietnam market access, settlement, custody, and foreign ownership limits.

Compare brokers

Aveluro may earn a commission from broker partners. Market data and broker availability can change; confirm access before opening an account.

价格图表
流动性
10日平均成交量
41.4K
今日成交量
12.4K
较均值
0.30×
市值
₫945.3B
流动性
低

流动性较低 — 日均成交量偏薄，较大订单可能带来更宽买卖价差和价格冲击。

新闻情绪
已分析文章
3
主要情绪
Positive
Positive 2
Neutral 1
最新新闻
完整分析 strategic partnership May 13, 2026
Bidiphar (DBD) 携手Citek启动大规模数字化转型，升级SAP S/4HANA云系统

DBD partners with Citek to launch a comprehensive digital transformation project, upgrading to SAP S/4HANA Private Cloud and implementing CSV, IFRS, and BI systems. This initiative aims to standardize operations, enhance transparency, and meet international pharmaceutical standards, positioning DBD for sustainable growth.

5 +5.0 Positive
阅读完整分析 →
完整分析 capital raise Apr 17, 2026
Bidiphar (DBD) 拟私募融资1.165万亿越南盾，投资两大制药厂项目

Bidiphar (DBD) will propose a private placement of 23.3 million shares to raise approximately VND 1,165 billion at a minimum price of VND 50,000 per share, targeting up to five professional investors. The capital is earmarked to fund two key pharmaceutical factory projects with a combined budget of VND 1,710 billion, as the company seeks to expand its production capacity following a year of revenue shortfall against plan.

6 Neutral
阅读完整分析 →
Apr 10, 2026
4 Positive
相关股票 — Dược phẩm
DCL Dược phẩm Cửu Long stock analysis DHG Dược Hậu Giang stock analysis DMC Xuất nhập khẩu Y tế Domesco stock analysis IMP Dược phẩm Imexpharm stock analysis LDP Dược Lâm Đồng - Ladophar stock analysis MED Dược Trung ương Mediplantex stock analysis TRA Traphaco stock analysis
股票分析
DBD stock news Vietnam 仪表板 Vietnam stocks for foreigners Foreign ownership limits

所有信息仅供参考，不构成投资建议。过往表现不代表未来收益。数据来源于越南公开市场信息。

最后更新: 2026-06-06T01:32:50Z.

关于 · 方法论 · 隐私